Modular Medical Enters Agreements With All Three Largest PBMs for Pivot Pump
Modular Medical said it has agreements with all three of the nation’s largest pharmacy benefit managers for its Pivot tubeless patch pump, while individual coverage remains subject to plan rules.
Modular Medical, Inc. (NASDAQ:MODD) said on November 19, 2026, that it has entered into agreements with the remaining two of the nation’s three largest pharmacy benefit managers (PBMs) for its Pivot tubeless patch pump. The company said the arrangements extend previously announced coverage across commercial, Medicare and Medicaid plans.
With the latest agreements, Modular Medical said all three of the largest PBMs now have arrangements covering Pivot. Their networks collectively cover more than 182 million lives and process approximately 80% of U.S. prescription claims, according to the company’s announcement.
The arrangements do not mean that every patient will receive coverage. Modular Medical said eligibility for an individual remains dependent on the formulary decision and benefit design of the relevant health plan or plan sponsor.
Jeb Besser, Modular Medical’s chief executive officer, said the agreements provide a basis for wider access to Pivot through standard pharmacy benefits and support the company’s commercial rollout over the coming year.
Mark Brady, the company’s director of managed markets, said access is an important factor in the adoption of insulin pump therapy. He linked the agreements to Modular Medical’s stated aim of making Pivot accessible and affordable for people who currently manage diabetes with multiple daily injections.
Modular Medical describes itself as a commercial-stage medical device company developing insulin delivery technologies intended to simplify diabetes management and increase access to pump therapy.
Pivot is a tubeless patch pump designed for people requiring intensive insulin therapy. The company says the product was developed to address barriers that have limited wider use of insulin pumps among patients using multiple daily injections.
Modular Medical said the potential benefits of the PBM agreements depend on whether health plans and plan sponsors adopt formulary coverage for Pivot. The company also identified the agreements’ terms, duration and potential termination, as well as reimbursement levels and pricing pressure, as factors that could affect their outcome.
Other risks listed by the company include the timing and success of Pivot’s commercial launch, market acceptance of its products and services, anticipated consumer demand, its ability to manufacture at high volumes and its ability to obtain sufficient capital to fund operations and commercialisation.
Modular Medical announced that it had entered into agreements with the remaining two of the nation’s three largest pharmacy benefit managers (PBMs) for its Pivot™ tubeless patch pump. The agreements expand upon previously announced coverage and cover commercial, Medicare and Medicaid plans through the PBM networks.
Modular Medical said it has now entered into agreements with all three of the nation’s largest PBMs for Pivot. Their networks collectively cover more than 182 million lives and process approximately 80% of U.S. prescription claims.
The agreements establish coverage across commercial, Medicare and Medicaid plans. Coverage for any individual patient remains subject to the formulary decisions and benefit design of the applicable health plan or plan sponsor.
Modular Medical said the agreements represent a significant milestone and support its efforts to drive adoption of Pivot across the U.S. healthcare landscape. The company also said the agreements establish a foundation for broader patient access through standard pharmacy benefits.
Jeb Besser, Chief Executive Officer of Modular Medical, said that securing agreements with all three of the nation’s largest PBMs was a significant milestone in expanding access to Pivot. He said the contracts support the company’s commercial rollout over the coming year.
Mark Brady, Director of Managed Markets at Modular Medical, said access remains one of the most important factors influencing adoption of insulin pump therapy. He said the agreements support the company’s strategy of making Pivot accessible and affordable and could help reduce traditional coverage barriers for patients moving from multiple daily injections to pump therapy.
Modular Medical is a commercial-stage medical device company focused on developing insulin delivery technologies intended to simplify diabetes management and increase access to insulin pump therapy. Its Pivot™ tubeless patch pump is designed to provide a user-friendly, flexible and accessible approach to insulin delivery for people requiring intensive insulin therapy.
Modular Medical shares trade on NASDAQ under the ticker symbol MODD, identified in the announcement as NASDAQ:MODD.
Modular Medical said it is preparing for the full commercial launch of Pivot. The company said the PBM contracts support its commercial rollout over the coming year.
Modular Medical said the anticipated benefits of the agreements could be affected by factors including whether health plans and plan sponsors adopt formulary coverage for Pivot, the terms, duration and potential termination of the agreements, reimbursement levels and pricing pressure. The company also identified risks relating to the timing and success of the commercial launch, product acceptance, manufacturing at high volumes and obtaining sufficient capital to fund operations and commercialisation.
Modular Medical said coverage for any individual patient remains subject to the formulary decisions and benefit design of the applicable health plan or plan sponsor. The company therefore did not state that the PBM agreements guarantee coverage for every patient.